Obagi® saypha® ChIQ™ is the latest FDA-approved HA filler for cheek augmentation, but entry into a crowded midface filler market demands a rigorous evaluation framework. This article walks through the clinical questions every injector should ask before adding a new product.
Burnout in insurance-based medicine isn’t new — but what physicians are doing about it is changing. Providers from emergency medicine, urology, OB/GYN, family medicine, and beyond are adding aesthetic medicine as a cash-pay, patient-driven complement to their existing practice.
Not all regenerative aesthetics treatments are created equal — and in 2026, the evidence gap between them is wider than most product reps will tell you. Here’s an honest evidence rating for every major regenerative modality, plus a practical framework for talking to patients about what you can and can’t confidently offer.
This clinical reference guide covers the FDA-approved indications, reconstitution protocols, dosing, off-label applications, technique principles, and patient screening criteria for Botox® Cosmetic (onabotulinumtoxinA), updated to reflect the October 2024 prescribing information. It is written for licensed aesthetic providers — MDs, DOs, NPs, PAs, RNs, and dentists — who are entering aesthetic injection practice or conducting a clinical knowledge review.
A recombinant botulinum toxin type A called YY001 recently completed a Phase III trial showing favorable efficacy and safety results compared to onabotulinumtoxinA for glabellar lines. While the product is not available in the United States, understanding how recombinant toxins differ from traditional formulations helps aesthetic providers evaluate emerging data and marketing claims.
Patients are already asking about the salmon facial. Here’s what the clinical evidence shows, why the U.S. entry point is lower than most providers expect, and how to evaluate it as a revenue opportunity for your practice.
PDRN salmon facials are showing up in patient consultations whether providers are ready or not — and the practices that get ahead of it now stand to gain a high-margin, high-retention treatment with minimal barrier to entry. Here’s everything you need to know to make an informed decision about adding it to your menu.
Relfydess (relabotulinumtoxinA) is a ready-to-use, complex-free liquid neurotoxin with Phase 3 data supporting rapid onset and sustained improvement for glabellar lines and crow’s feet in many patients. Here’s what aesthetic providers need to know about its clinical profile—and how to prepare their practice before adding it to the menu.
Relfydess (relabotulinumtoxinA) is a ready-to-use, complex‑free liquid neurotoxin that promises rapid onset and extended duration for glabellar lines and crow’s feet. This guide reviews the clinical evidence, practical dosing considerations, and practice‑management implications so you can decide where it fits in your neurotoxin portfolio.
The FDA approval of RADIESSE for décolletage wrinkle treatment marks the first time a biostimulatory filler has been cleared for both facial and body indications in the United States. This 2026 clinical guide covers every injectable and non-injectable option available — from SKINVIVE and Sculptra to fractional lasers and RF microneedling — with guidance on patient selection and combination protocols.